Composition for reducing harm of deoxynivalenol to immune function of offspring chicken as well as preparation method and application of composition

Abstract

The invention discloses a composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens, and is characterized in that the composition comprises the following components: a momordica grosvenori extract, a cinnamon extract, an origanum vulgare leaf extract and functional polypeptide, the mass ratio of the fructus momordicae extract to the cortex cinnamomi extract to the origanum vulgare leaf extract to the functional polypeptide is (1-5): (1-2): (1-2): (1-2). According to the invention, the combination of the natural plant extract and the functional polypeptide is screened, and the combination and the vaccine are injected together during embryo injection immunization, so that the harm of the residual DON in the hatching egg to the immunization of the broiler chicken is relieved, and meanwhile, the adverse effects of an inactivator in the vaccine and an embryo injection mode on the hatching egg are reduced, so that the titer of the vaccine is further improved.

Description

Technical Field

[0001] The invention belongs to the technical field of poultry hatching and breeding in animal husbandry, and in particular relates to a composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens, and a preparation method and application thereof. Background Art

[0002] In recent years, multiple studies have shown that the detection rate of deoxynivalenol (DON) residues in eggs is currently high, with the residual amount being approximately 0 to 10 μg / kg. DON can inhibit poultry humoral immunity, which is directly manifested in low vaccine potency and affects the health and growth of broilers.

[0003] As large poultry farming companies gradually shift from chick immunization to embryo egg injection immunization in the late stage of embryo incubation, there are also some problems with embryo egg immunization, such as the common inactivator formaldehyde in vaccines that easily affects the embryo, and the stimulation of early injection on the embryo. Therefore, how to eliminate the adverse effects of residual DON toxins in eggs on broiler immunity has become an important research topic.

[0004] Current research focuses on removing mycotoxins from feed, but it is difficult to remove mycotoxins from eggs. Therefore, it is feasible to find active substances that can reduce the harm of DON during embryonated egg immunization. Plant extracts have performed well in enhancing animal immunity, including monk fruit, cinnamon, oregano and peptides. Monk fruit has strong antioxidant and immunomodulatory effects, which can improve liver function and enhance the immune system. Cinnamon is known for its antibacterial, anti-inflammatory and immune-enhancing properties. Many studies have shown that the combination of carvacrol and cinnamaldehyde can effectively inhibit the growth of harmful bacteria and suppress inflammation, but plant essential oils have relatively poor inhibitory effects on fungal growth and have limitations in directly improving immunity. Peptides improve the overall health of animals by providing necessary amino acids, promoting protein synthesis and cell repair.

[0005] Based on the above background, the present invention proposes a composite plant extract combining monk fruit, cinnamon, oregano leaves and polypeptides, which is injected through embryo immunity to alleviate the harm of deoxynivalenol (DON) to commercial broilers and improve their immunity and health level. Summary of the invention

[0006] The presence of deoxynivalenol has been proven to reduce the potency of chick vaccines, and the automated method of injecting poultry disease vaccines into eggs has gradually become the mainstream. Therefore, the purpose of the present invention is to provide a composition for reducing the adverse effects of deoxynivalenol on animal immune function, and its preparation method and application, so as to improve the effect of commercial broiler vaccination, thereby improving their immunity and health level.

[0007] To this end, the present invention provides the following technical solutions.

[0008] One aspect of the present invention provides a composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens, the components of the composition include: monk fruit extract, cinnamon extract, oregano leaf extract and functional polypeptide; wherein the mass ratio of the monk fruit extract, cinnamon extract, oregano leaf extract and functional polypeptide is (1-5): (1-2): (1-2): (1-2).

[0009] As a preferred embodiment of the present invention, the mass ratio of the monk fruit extract, the cinnamon extract, the oregano leaf extract and the functional polypeptide is 1:1:1:1.

[0010] As a preferred embodiment of the present invention, the monk fruit extract is monk fruit saponin III.

[0011] As a preferred embodiment of the present invention, the cinnamon extract is cinnamaldehyde.

[0012] As a preferred embodiment of the present invention, the oregano leaf extract is carvacrol.

[0013] As a preferred embodiment of the present invention, the functional polypeptide is pigeon peptide.

[0014] As a preferred embodiment of the present invention, the preparation method of the pigeon peptide is:

[0015] (i) After conventional treatment, the pigeon liver is crushed and homogenized, and then mixed with pigeon blood collected during slaughter, and sodium hydroxide is added to adjust the pH to 10 to obtain a mixed homogenate; the obtained mixed homogenate is placed in an ultrasonic reactor for intermittent ultrasonic extraction to obtain an extraction solution;

[0016] (ii) subjecting the obtained extraction solution to a first centrifugation to obtain a first supernatant, adding a hydrochloric acid aqueous solution dropwise to the first supernatant until the isoelectric point of the protein is reached; subjecting the obtained first supernatant to a second centrifugation to obtain a second supernatant;

[0017] (iii) adding the composite enzyme preparation to the obtained second supernatant and performing enzymolysis, after the enzymolysis is completed, inactivating the enzyme, rapidly cooling, and centrifuging to obtain a third supernatant;

[0018] (iv) filtering the obtained third supernatant through an organic nanofiltration membrane, sterilizing and drying the obtained filtrate to obtain a pigeon-derived small molecule polypeptide with a molecular weight of ≤1 kDa, namely, pigeon peptide.

[0019] As a preferred embodiment of the present invention, in step (i), the pigeon liver and pigeon blood are mixed in a mass ratio of 1:1 to 5.

[0020] As a preferred embodiment of the present invention, in step (i), the intermittent ultrasonic extraction method is: extraction is carried out at a power of 600 to 1000 W in a manner of ultrasonicating for 5 minutes and stopping for 1 minute, and the total extraction time is 60 to 90 minutes.

[0021] As a preferred embodiment of the present invention, in step (ii), the first centrifugation condition is: rotation speed 8000-12000 rpm, time 10-20 min.

[0022] As a preferred embodiment of the present invention, in step (ii), the second centrifugation condition is: rotation speed 8000-12000 rpm, time 10-20 min.

[0023] As a preferred embodiment of the present invention, in step (iii), the composite enzyme preparation is composed of neutral protease, alkaline protease and pancreatic enzyme in a mass ratio of 1:(1-2):(1-2).

[0024] As a preferred embodiment of the present invention, in step (iii), the enzymatic hydrolysis conditions are: temperature 50-70° C., time 4-6 h.

[0025] As a preferred embodiment of the present invention, in step (iv), the molecular weight of the organic nanofiltration membrane is 150 to 1000 Da, and the operating pressure is 0.5 to 2.5 MPa.

[0026] As a preferred embodiment of the present invention, the composition further contains an emulsifier.

[0027] As a preferred embodiment of the present invention, the emulsifier includes sorbitan fatty acid ester emulsifiers, including Span20, Span40, Span60, Span65, Span80, and Span85.

[0028] Another aspect of the present invention provides a product for reducing the harm of deoxynivalenol to the immune function of offspring chickens, comprising the composition as described above, and acceptable auxiliary materials.

[0029] Another aspect of the present invention provides a use of the above-mentioned composition in the preparation of a product that reduces the harm of deoxynivalenol to the immune function of offspring chickens.

[0030] By means of the above technical solution, the present invention has at least the following advantages:

[0031] 1. The present invention aims to alleviate the harm of DON residual in eggs to broiler immunity by screening a combination of natural plant extracts and functional polypeptides and injecting them together with vaccines during embryo injection immunization, while reducing the adverse effects of inactivators (especially formaldehyde) in vaccines and embryo injection methods on eggs, thereby further improving the potency of the vaccine.

[0032] 2. The present invention selects momordica saponins, carvacrol and cinnamaldehyde with anti-inflammatory and antioxidant activities as the main plant extracts, combined with pigeon product polypeptides (pigeon liver and blood extracts) that directly enhance immunity, and co-injects them with vaccines in the late incubation of breeding eggs. It can partially neutralize the common inactivators in vaccines, reduce oxidative damage during the injection process, and directly enhance the humoral immunity of chicken embryos, forming a new embryonic immune injection strategy.

[0033] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 These are stained sections of the bursa of Fabricius of chicks (×400 times), wherein A: non-toxin-free non-immunized group, B: non-toxin-containing group, C: toxin-containing vaccine + normal saline group, D: toxin-containing vaccine + Example 2 group, E: toxin-containing vaccine + Example 4 group, and F: toxin-containing vaccine + Example 1 group. DETAILED DESCRIPTION

[0035] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] 1. Raw materials and sources

[0037] 1.1 Commercially available raw materials

[0038] Unless otherwise specified, the following three raw materials are commercially available, namely:

[0039] Carvacrol, food grade raw material, purity >98%.

[0040] Cinnamaldehyde, food grade raw material, purity>98%.

[0041] Mogroside is Mogroside III, food grade raw material, purity> 98%.

[0042] Chicken Newcastle disease live vaccine 4 series La Sota10 6 EID 50 / mL.

[0043] 1.2 Homemade raw materials

[0044] Based on the use and purpose of the final invention, the preparation of pigeon peptide is based on the following standards: 1. It comes from organs or tissues with abundant immune cells; 2. There is no need to consider palatability and smell; 3. The antioxidant capacity of the final peptide needs to be improved as much as possible.

[0045] Therefore, unless otherwise specified, the pigeon peptide used in the present invention is a homemade product, and a preferred preparation process is as follows:

[0046] (i) After conventional treatment, the pigeon liver is crushed and homogenized, and then mixed with pigeon blood collected during slaughter in a mass ratio of 1:3, and sodium hydroxide is added to adjust the pH to 10 to obtain a mixed homogenate; the obtained mixed homogenate is placed in an ultrasonic reactor and subjected to intermittent ultrasonic extraction for 90 minutes at a power of 800 W in a manner of 5 minutes of ultrasonication and 1 minute of rest to obtain an extraction solution.

[0047] (ii) The obtained extraction solution was centrifuged at 10,000 rpm for 15 min to obtain a first supernatant, and a hydrochloric acid aqueous solution was added dropwise to the first supernatant until the isoelectric point of the protein was reached; the obtained first supernatant was further centrifuged at 10,000 rpm for 15 min to obtain a second supernatant.

[0048] (iii) adding a composite enzyme preparation (composed of neutral protease, alkaline protease and pancreatic enzyme in a mass ratio of 1:1.5:1.5) to the obtained second supernatant and performing enzymolysis at 60°C for 5 hours. After the enzymolysis is completed, the enzyme is inactivated, the mixture is rapidly cooled, and centrifuged at 20,000 rpm for 10 minutes to obtain a third supernatant.

[0049] (iv) filtering the obtained third supernatant through an organic nanofiltration membrane with a molecular weight of 1000Da at an operating pressure of 1.5Mpa, and sterilizing and drying the obtained filtrate to obtain a pigeon-derived small molecule polypeptide with a molecular weight of ≤1kDa, i.e., pigeon peptide.

[0050] Embodiment 1:

[0051] Preparation of the composition: Mixing mogroside, cinnamaldehyde, carvacrol and pigeon peptide in a mass ratio of 1:1:1:1 to obtain a mixed essential oil.

[0052] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0053] Embodiment 2:

[0054] Preparation of the composition: Mixing mogroside, cinnamaldehyde, carvacrol and pigeon peptide in a mass ratio of 5:2:1:1 to obtain a mixed essential oil.

[0055] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0056] Embodiment 3:

[0057] Preparation of a composition: Mixing mogroside, cinnamaldehyde, carvacrol and pigeon peptide in a mass ratio of 3:1:1:1 to obtain a mixed essential oil.

[0058] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0059] Embodiment 4:

[0060] Preparation of the composition: Mixing mogroside, cinnamaldehyde, carvacrol and pigeon peptide in a mass ratio of 1:1:1:1 to obtain a mixed essential oil.

[0061] The mixed essential oil, the emulsifier Span20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0062] Comparative Example 1:

[0063] The only difference from Example 1 is that mogroside is replaced with astragalus polysaccharide (food grade raw material, purity> 98%), and the rest is consistent with Example 1, namely:

[0064] Preparation of the composition: Astragalus polysaccharide, cinnamaldehyde, carvacrol and pigeon peptide are mixed in a mass ratio of 1:1:1:1 to obtain a mixed essential oil.

[0065] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0066] Comparative Example 2:

[0067] The only difference from Example 1 is that carvacrol is replaced by allicin (food grade raw material, purity> 98%), and the rest is consistent with Example 1, namely:

[0068] Preparation of the composition: Mixing mogroside, cinnamaldehyde, allicin and pigeon peptide in a mass ratio of 1:1:1:1 to obtain a mixed essential oil.

[0069] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0070] Comparative Example 3:

[0071] The only difference from Example 1 is that the pigeon peptide is replaced with soybean glycopeptide (food grade raw material, purity> 98%), and the rest is consistent with Example 1, namely:

[0072] Preparation of the composition: Mixing mogroside, cinnamaldehyde, carvacrol and soybean glycopeptide in a mass ratio of 1:1:1:1 to obtain a mixed essential oil.

[0073] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0074] Comparative Example 4:

[0075] The only difference from Example 1 is that no pigeon peptide is added, and the rest is consistent with Example 1, namely:

[0076] Preparation of the composition: Mixing mogroside, cinnamaldehyde and carvacrol in a mass ratio of 1:1:1 to obtain a mixed essential oil.

[0077] The mixed essential oil, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain a composition.

[0078] Comparative Example 5:

[0079] The only difference from Example 1 is that only pigeon peptide is added, and the rest is consistent with Example 1, namely:

[0080] Preparation of the composition: Pigeon peptide, emulsifier Tween-20 and water are mixed in a mass ratio of 1:4:5 to obtain the composition.

[0081] Test 1: In vitro antioxidant assay

[0082] The antioxidant properties of the compositions of Examples 1-3 and Comparative Examples 1-5 were tested respectively. The free radical scavenging rate was measured according to the DPPH method. The specific method was based on the study on the antioxidant properties of oregano oil, carvacrol, citral and cinnamaldehyde disclosed by Wang Xinwei et al. The concentration of each composition was 8 g / L during the test. The results are shown in Table 1:

[0083] Table 1 Statistics of DPPH removal rates of different compositions

[0084]

[0085] From the results in Table 1, it can be seen that the free radical scavenging rates of the compositions of Examples 1 to 4 are significantly higher than those of Comparative Examples 1 to 5. The above results indicate that the four raw materials in the composition of the present invention have a synergistic effect, thereby significantly improving the antioxidant performance of the composition.

[0086] Experiment 2: Effects of DON on egg hatching and chick growth performance

[0087] 1. Reagent preparation:

[0088] DON was diluted to 5 ng / mL using ultrapure water to obtain a DON solution.

[0089] Dilute the Newcastle disease vaccine to 10% using 0.9% saline. 4 EID 50 / mL.

[0090] 2. Chicken embryo incubation conditions:

[0091] The sterilized commercial broiler eggs were placed in a HXC-5 microcomputer fully automatic incubation controller. The incubation conditions were as follows: temperature 37.6±0.1°C, relative humidity 60%, turning the eggs every 1.5 hours, and stopping turning the eggs and placing them in the tray on the 19th day of incubation.

[0092] 3. Grouping and injection of embryo eggs:

[0093] On the 15th day of incubation, 20 eggs were divided into two groups: a toxin group and a toxin-free group, with 10 eggs in each group; the eggs in the toxin group were injected with DON from the air chamber. The specific operation was as follows: mark the position of the air chamber, disinfect the injection site with 75% alcohol, vertically punch a hole and inject 0.2mL of 5ng / mL DON solution vertically downward into the air chamber using a disposable syringe, and the injection depth was about 0.3cm. After the injection of each embryonated egg, the injection hole was sealed with sterile liquid paraffin, and the entire operation time was controlled within 30min and sent to the incubator. No operation was performed in the toxin-free group. The eggs were illuminated again on the 17.5th day of incubation, and the Newcastle disease vaccine (injection volume was 0.15ml) was uniformly injected from the air chamber.

[0094] 4. Result detection

[0095] Vaccine titer determination according to "Newcastle disease diagnostic technology GB / T 16550-2008": Aseptically collect blood from 2-3 SPF or unimmunized adult roosters, 2 mL per rooster, anticoagulate with heparin and centrifuge at 2000rpm for 10 minutes, discard the supernatant layer and the white blood cell layer, wash the precipitate with sterile saline for 3 times, and the precipitate is the chicken red blood cells. Mix the saline and chicken red blood cells at a ratio of 99:1 to obtain a 1% chicken red blood cell suspension. Add 50 μL of PBS solution to each well on a 96-well micro-hemagglutination plate, add 50 μL of the serum to be tested to the first well and mix thoroughly, and dilute horizontally to the 11th well; add 50 μL of 4 units of Newcastle disease antigen and 50 μL of 1% chicken red blood cell suspension to each well in turn, shake and mix, and place in a 37°C incubator for 30 minutes. At the same time, set up positive and negative serum and blank control wells. Interpretation of results: The maximum dilution of serum that inhibits agglutination by 100% is the HI antibody titer of the serum.

[0096] Healthy chick rate is the percentage of healthy newborn chicks in the total number of chicks. Healthy chicks refer to chicks that hatch on time, have normal down feathers, well-healed navels, are lively, and have no deformities. The vaccine potency detection method uses the hemagglutination test (HA) and hemagglutination inhibition test (HI) methods specified in GB / T 16550-2020 "Newcastle disease diagnostic technology" for antibody detection. The results are shown in Table 2-5.

[0097] Table 2 Effects of different treatments on hatching rate, healthy chick rate and mortality rate of chicks after embryo injection

[0098]

[0099] From the results in Table 2, it can be seen that compared with the toxin-free group, the injection of 5 ng / ml DON had no significant effect on the hatching rate and mortality of the eggs, but there was a trend to reduce the healthy chick rate.

[0100] Table 3 Effects of different treatments on vaccine titers in chicks after embryo injection

[0101]

[0102] The results in Table 3 indicate that the presence of 5 ng / mL DON reduced the vaccine titer compared to the toxin-free group.

[0103] Table 4 Effects of different treatments on chick growth performance after embryo injection

[0104]

[0105] The results in Table 4 show that, compared with the toxin-free group, the presence of 5 ng / mL DON had a certain downward trend on the hatch weight, final chick weight and average daily weight gain.

[0106] Table 5 Effects of different treatments on immune function of chicks after embryo injection

[0107]

[0108] The results in Table 5 show that, compared with the toxin-free group, the presence of 5 ng / mL DON has a tendency to reduce the immune organ index.

[0109] In summary, it can be seen from the results in Tables 1 to 4 that the presence of DON in eggs has little effect on the hatchability and growth performance of broiler chickens, but embryonic vaccination will affect the hatchability and reduce the potency of Newcastle disease vaccine in the presence of DON.

[0110] Experiment 3: Effects of different combination vaccines on egg hatching, chick growth performance and immune performance

[0111] 1. Test method: Same as Example 2, specifically:

[0112] The sterilized commercial broiler eggs were placed in a HXC-5 microcomputer fully automatic hatching controller. The hatching conditions were: temperature 37.6 ± 0.1 ° C, relative humidity 60%, egg turning once every 1.5 hours, and egg turning and dropping were stopped on the 19th day of incubation. On the 15th day of incubation, all eggs were injected with DON from the air chamber. The specific operation was as follows: mark the position of the air chamber, use 75% alcohol to disinfect the injection site, and vertically punch 0.2mL 5ng / mL DON solution into the air chamber vertically downward using a disposable syringe. The injection depth was about 0.3cm. After each embryo egg was injected, the injection hole was sealed with sterile liquid paraffin, and the entire operation time was controlled to be within 30min and sent to the incubator. The eggs were illuminated again on 17.5 days, the dead embryo eggs were removed, and 50 live embryo eggs were randomly divided into 5 groups, 10 eggs in each group. The groups were divided into the following groups: saline control group, Example 1-4 and Comparative Example 1-5 groups, as follows:

[0113] Normal saline control group: injected with normal saline (0.15 mL) and vaccine (0.15 mL) on 17.5 days;

[0114] Example group: 17.5d, the composition solution (0.15 mL) and vaccine (0.15 mL) of Examples 1-4 and Comparative Examples 1-5 were injected respectively;

[0115] According to the injection method of each group, each combination and vaccine were injected again. Before injection, each combination and vaccine were heated at 40°C to form a combined immune injection solution composed of different combinations. On the 18th day (17.5 days), the combination was injected from the air chamber to the allantoic cavity and continued to incubate. The hatching rate and healthy chick rate were recorded.

[0116] 2. Detection method

[0117] Growth performance: On the first and seventh days of the experiment, the chickens were weighed on an empty stomach before morning feeding at 9:00 a.m., the feed consumption of each group was recorded, and the average daily gain (ADG), average daily feed intake (ADFI) and feed-to-weight ratio (F / G) of the chickens were calculated.

[0118] Immune organ index: The weights of spleen, thymus and bursa of Fabricius of 7-day-old chicks in each group were recorded, and the immune organ index was calculated.

[0119] Observation of immune organ sections: The bursa of Fabricius is the main immune organ in the early stage of chicks. The bursa of Fabricius in slaughtered chickens was routinely sectioned and stained for observation.

[0120] 3. Test results

[0121] 3.1 Hatching rate and healthy chick rate. The results are shown in Table 6.

[0122] Table 6 Effects of different treatments on hatching rate, healthy chick rate and mortality rate after embryo injection

[0123]

[0124] The results of Table 6 show that, compared with the non-immunized group, the embryonated egg injection of toxin or Newcastle disease vaccine does not affect the hatching rate and mortality rate of chicks. However, compared with the non-immunized group, by adding different compositions and vaccine combined action, embryonated egg immunization will reduce the hatching rate of eggs, and compared with Examples 1-4, the addition of the compositions of Comparative Examples 1-5 will affect the hatching rate and the hatching rate of eggs to varying degrees. It can be seen that the compositions of Examples 1-4 of the present invention and the vaccine combined action can improve the hatching rate and the hatching rate of eggs.

[0125] 3.2 Effect on vaccine titer. The results are shown in Table 7.

[0126] Table 7 Effects of different treatments on vaccine titers in chicks after embryo injection

[0127]

[0128]

[0129] Vaccine titer directly reflects the ability of poultry humoral immunity. As can be seen from Table 7, in each group of embryo injection of DON toxin, the addition of the composition of Examples 1-4 and Comparative Examples 1-5 enhanced the vaccine titer to a certain extent compared with the saline group, and compared with Comparative Examples 1-5, the addition of the composition of Examples 1-4 can significantly increase the vaccine titer. The above results show that the combined injection of the composition of Examples 1-4 of the present invention, especially Example 4, and the vaccine can significantly improve the immune response of chicken embryos.

[0130] 3.3 Effects on the growth performance of chicks. The results are shown in Table 8.

[0131] Table 8 Effects of different treatments on chick growth performance after embryo injection

[0132]

[0133] The results in Table 8 show that in each group of embryos injected with DON toxin, the addition of the compositions of Examples 1-4 and Comparative Examples 1-5 enhanced the growth performance of chicks (including hatching weight, final weight and average daily weight gain) to a certain extent compared with the saline group, and compared with Comparative Examples 1-5, the addition of the compositions of Examples 1-4 can significantly improve the growth performance of chicks. The above results show that the combined injection of the compositions of Examples 1-4, especially Example 4, of the present invention and the vaccine can more significantly improve the growth performance of chicks.

[0134] 3.4 Effects on immune organs. The results are shown in Tables 9 and Figure 1 .

[0135] Table 9 Effects of different treatments on immune organ indexes of chicks after embryo injection

[0136]

[0137] The results in Table 9 show that compared with the control group, the chick immune organ indexes of Examples 1-4 and Comparative Examples 1-5 were all improved. And compared with Comparative Examples 1-5, the addition of the composition of Examples 1-4 can significantly improve the chick immune organ index. The above results show that the combined injection of the composition of Examples 1-4, especially Example 4, and the vaccine of the present invention can more significantly improve the immune performance of chicks.

[0138] like Figure 1 As shown, the bursal nodules of the chickens in the control group that were not treated with toxins and vaccines were larger and more closely arranged (A), and the bursal nodules of the chickens that were injected with toxins (B) and Newcastle disease vaccines (C) were of varying sizes. However, the volume of the lymph nodes of the chickens treated with the composition of Example 2 (D), the composition of Example 4 (E), and the composition of Example 1 (F) recovered to a level close to that of the control group and became regular, with thicker cortex and developed folds, especially in the polypeptide group.

[0139] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens, characterized in that: The composition comprises: monk fruit extract, cinnamon extract, oregano leaf extract and functional polypeptide, wherein the mass ratio of the monk fruit extract, cinnamon extract, oregano leaf extract and functional polypeptide is (1-5): (1-2): (1-2): (1-2).

2. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1, characterized in that: The mass ratio of the monk fruit extract, the cinnamon extract, the oregano leaf extract and the functional polypeptide is 1:1:1:

1.

3. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1 or 2, characterized in that: The monk fruit extract is monk fruit saponin III.

4. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1 or 2, characterized in that: The cinnamon extract is cinnamaldehyde.

5. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1 or 2, characterized in that: The oregano leaf extract is carvacrol.

6. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1 or 2, characterized in that: The functional polypeptide is a polypeptide extracted from pigeon liver and pigeon blood.

7. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 1 or 2, characterized in that: The composition also contains an emulsifier.

8. The composition for reducing the harm of deoxynivalenol to the immune function of offspring chickens according to claim 7, characterized in that: The emulsifier includes sorbitan fatty acid ester emulsifiers, including Span20, Span40, Span60, Span65, Span80, and Span85.

9. A product for reducing the harm of deoxynivalenol to the immune function of offspring chickens, characterized in that: The invention comprises the composition according to any one of claims 1 to 8, and acceptable auxiliary materials.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of a product for reducing the damage of deoxynivalenol to the immune function of offspring chickens.

Images